Towards vaccines against human papillomavirus type-16 genital infections.
Human papillomavirus type-16 (HPV-16) is strongly associated with cervical carcinoma and cervical intraepithelial neoplasia. It may soon be possible to develop prophylactic vaccines designed to induce neutralizing antibodies to HPV-16 virions in genital secretions and therapeutic vaccines to induce cytotoxic T-cell responses against HPV-16 early proteins in cervical intraepithelial neoplasia and cervical cancers. Although significant advances have been achieved, problems remain before such vaccines can be used routinely.
Cason
J
J
Richard DimbleBy Laboratory of Cancer Virology, United Medical and Dental Schools, Rayne Institute, London, UK.
Khan
S A
SA
Best
J M
JM
D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D002278:Carcinoma in Situ / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control / Q000628:therapy*; D005260:Female; D006801:Humans; D009856:Oncogene Proteins, Viral / Q000276:immunology; D027383:Papillomaviridae / Q000276:immunology* / Q000502:physiology; D050725:Papillomavirus E7 Proteins; D053918:Papillomavirus Vaccines; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014412:Tumor Virus Infections / Q000276:immunology / Q000517:prevention & control / Q000628:therapy*; D002577:Uterine Cervical Diseases / Q000276:immunology / Q000517:prevention & control / Q000628:therapy*; D002583:Uterine Cervical Neoplasms / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control / Q000628:therapy*; D014614:Vaccines, Synthetic / Q000276:immunology / Q000627:therapeutic use; D014765:Viral Vaccines / Q000276:immunology / Q000627:therapeutic use; D014779:Virus Replication
D000914:Antibodies, Viral; D009856:Oncogene Proteins, Viral; D050725:Papillomavirus E7 Proteins; D053918:Papillomavirus Vaccines; D014614:Vaccines, Synthetic; D014765:Viral Vaccines; C059731:oncogene protein E7, Human papillomavirus type 16